Literature DB >> 1751206

Uremic myopathy and calcitriol therapy in CAPD patients.

M Bertoli1, G Luisetto, V Arcuti, M Urso.   

Abstract

During 7 months of calcitriol treatment in eight CAPD patients, significant increases in serum creatinine and daily excretion of this substance in dialysis fluid were observed, but there was a significant decrease in creatinine in the urinary daily output. When therapy was stopped, creatinine levels fell to baseline in serum and peritoneal fluid, and urine values continued to decrease as previously observed. Dynamometric performance showed a significant increase during treatment, which remained after drug withdrawal. These findings suggest that the transient increase of serum creatinine during calcitriol treatment may be a result of an increased production and release of this metabolite from muscle.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1751206

Source DB:  PubMed          Journal:  ASAIO Trans        ISSN: 0889-7190


  3 in total

1.  The effect of active vitamin D administration on muscle mass in hemodialysis patients.

Authors:  Atsushi Mori; Tomoya Nishino; Yoko Obata; Masayuki Nakazawa; Misaki Hirose; Hiroshi Yamashita; Tadashi Uramatsu; Ken Shinzato; Shigeru Kohno
Journal:  Clin Drug Investig       Date:  2013-11       Impact factor: 2.859

2.  Relationship between vitamin D and muscle size and strength in patients on hemodialysis.

Authors:  Patricia L Gordon; Giorgos K Sakkas; Julie W Doyle; Tiffany Shubert; Kirsten L Johansen
Journal:  J Ren Nutr       Date:  2007-11       Impact factor: 3.655

3.  VITADIAL "Does correction of 25 OH-VITAmin D with cholecalciferol supplementation increase muscle strength in hemoDIALysis patients?": study protocol for a randomized controlled trial.

Authors:  Stanislas Bataille; Nathalie Pedinielli; Elisa Carreno; Mathilde Prezelin-Reydit; Philippe Chauveau; Guillaume Jean; Thomas Robert; Mickaël Bobot; Guillaume Seret; Elisabeth Jouve; Frederic Lavainne; Marianne Serveaux; Laurence Vrigneaud; Stéphanie Gentile
Journal:  Trials       Date:  2021-05-25       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.